Patients with desmoid tumors face significant clinical and economic burdens, impacting their quality of life and leading to ...
During a recent AJMC Peer Exchange, a panel of experts delved into the clinical characteristics and heterogeneity of desmoid tumors, the importance of a multidisciplinary approach in both ...
FOG-001 received fast track designation after early study results showed tumor shrinkage in all evaluable patients with ...
Barely two months after SpringWorks Therapeutics secured the first-ever FDA approval for a drug to treat ultra-rare desmoid tumors, Immunome has bagged the rights to a phase 3 therapy it claims could ...
FOG-001 is an investigational first-in-class competitive inhibitor of β-catenin interactions with the TCF family of transcription factors and is currently in clinical development. FOG-001 is intended ...
GRAND RAPIDS, MI – A year ago, Gabe Augdahl struggled with not feeling like a “normal” teenager. Augdahl, then a senior at West Catholic High School, had a rare tumor on his neck with no cure, and it ...
Prognostic Factors for the Outcome of Chemotherapy in Advanced Soft Tissue Sarcoma: An Analysis of 2,185 Patients Treated With Anthracycline-Containing First-Line Regimens—A European Organization for ...
LEXINGTON, Ky. (LEX 18) — Diagnosed with a rare condition at age 18, Mackenzie Wilmoth has recovered, and she's leading the efforts to help those dealing with Pediatric Cancer. Wilmoth was in a ...
Shares of Immunome, Inc. IMNM were up 36.9% on Feb 6 after the company announced that it has entered into a definitive asset purchase agreement with Wilmington, DE-based oncology company Ayala ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback